Skip to content

Nuvation Bio NUVB Available for sale investments

Available for sale investments at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
Nektar Therapeutics logo
Nektar TherapeuticsNKTR

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.25B+150%
Enterprise value$2.18B+154%
P/S15.7×-66.3×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's available for sale investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's available for sale investments?
Nuvation Bio (NUVB) reported available for sale investments of $461.45M in Q4 2025.
How has Nuvation Bio's available for sale investments changed year-over-year?
Nuvation Bio's available for sale investments decreased by 3.6% year-over-year, from $478.52M to $461.45M.
What is the long-term trend for Nuvation Bio's available for sale investments?
Over 5 years (2020 to 2025), Nuvation Bio's available for sale investments has grown at a 18.6% compound annual growth rate (CAGR), from $196.4M to $461.45M.